Impending completion of merger between Genome Therapeutics and Genesoft Pharmaceuticals
Published: 2004-02-05 07:00:00
Updated: 2004-02-05 07:00:00
The newly merged company between Genome Therapeutics (Nasdaq: GENE) and Genesoft Pharmaceuticals, a privately-held pharmaceutical company based in San Francisco of the United States, is set to launch on and about this March, market sources said recently.
The completion of the merger remains su...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
